Literature DB >> 10475065

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.

J Brieger1, E J Weidt, P Schirmacher, S Störkel, C Huber, H J Decker.   

Abstract

Tumors associated with the VHL (von Hippel-Lindau) disease, such as hemangioblastomas and renal carcinomas and their sporadic counterparts, are cystic and well vascularized. Mutations of the VHL tumor-suppressor gene and elevated levels of vascular endothelial growth factor (VEGF) have been described in these tumors. The upregulation of VEGF has been shown in vitro as a consequence of alteration of the VHL gene. No comprehensive in vivo analysis has yet been carried out of the factors affecting tumor growth, vascularization, VEGF, and VHL expression. We performed immunohistochemistry and mRNA studies on primary sporadic renal carcinomas and matching normal renal tissue. We semiquantitatively analyzed 29 renal carcinomas (22 clear cell, 5 chromophilic, 2 chromophobic tumors) for VHL mRNA, and VEGF expression for morphology and tumor size. Immunohistochemistry was carried out for VEGF protein expression, vascularization, and macrophage infiltration. Vascularization of the chromophilic renal carcinomas was lower than that of the clear cell type of renal carcinoma. Low VEGF protein expression was seen in four of the five chromophilic renal carcinomas. We found two groups of clear cell renal cell carcinoma: one with reduced VHL mRNA and increased VEGF mRNA, and the other without significantly altered VHL or VEGF mRNAs. Tumor vascularization was correlated with VEGF protein and seemed to be independent of macrophage infiltration. Our in vivo findings support the inverse relationship between the regulation of VHL and that of VEGF. Our data also indicate that there may be an VHL-independent pathway for the induction of tumor vascularization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475065     DOI: 10.1007/s001099900022

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  10 in total

Review 1.  Angiogenic molecules and mechanisms in breast cancer.

Authors:  I Wu; M A Moses
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

3.  Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.

Authors:  H Kanayama; S Yano; S J Kim; S Ozawa; L M Ellis; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

4.  Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.

Authors:  Peter Schraml; Alexander Hergovich; Florian Hatz; Mahul B Amin; So D Lim; Wilhelm Krek; Michael J Mihatsch; Holger Moch; Alexander Hergovitz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.

Authors:  Börje Ljungberg; Jan Jacobsen; Stina Häggström-Rudolfssson; Torgny Rasmuson; Gudrun Lindh; Kjell Grankvist
Journal:  Urol Res       Date:  2003-09-13

Review 6.  [Microarrays for the identification of molecular markers in the diagnosis and therapy of renal cell carcinomas].

Authors:  H Sültmann; A Poustka
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

Review 7.  Axitinib for the management of metastatic renal cell carcinoma.

Authors:  Bernard Escudier; Martin Gore
Journal:  Drugs R D       Date:  2011

Review 8.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

9.  Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor gene.

Authors:  Daekyu Sun; Kexiao Guo; Yoon-Joo Shin
Journal:  Nucleic Acids Res       Date:  2010-10-18       Impact factor: 16.971

10.  Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma.

Authors:  Gordana Dorević; Koviljka Matusan-Ilijas; Emina Babarović; Ita Hadzisejdić; Maja Grahovac; Blazenka Grahovac; Nives Jonjić
Journal:  J Exp Clin Cancer Res       Date:  2009-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.